Get the Stockscreener App
41.94
2.37%
0.97
After Hours:
42.49
0.55
+1.31%
Crispr Therapeutics Ag Stock (CRSP) Latest News
2 No-Brainer Biotech Stocks to Buy Right Now - The Motley Fool
Is CRISPR Therapeutics (CRSP) One of the Most Shorted Stocks in 2025? - MSN
CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell? - Yahoo Finance
CRISPR Therapeutics AG (CRSP): A Bull Case Theory - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Trading 2.8% HigherHere's What Happened - MarketBeat
Crispr therapeutics CFO Prasad Raju sells $157,251 in shares By Investing.com - Investing.com South Africa
Crispr therapeutics CFO Prasad Raju sells $157,251 in shares - Investing.com
CRISPR Therapeutics CFO Sells Shares to Cover Tax Obligation - TradingView
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from Analysts - MarketBeat
CRISPR Therapeutics (CRSP): Among Top Stocks to Buy from Ark Invest’s Portfolio - Yahoo Finance UK
Nikko Asset Management Americas Inc. Decreases Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.9% After Insider Selling - MarketBeat
3 Gene Therapy Stocks to Watch Amid Industry Turmoil - Schaeffers Research
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 3.9%Should You Sell? - MarketBeat
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells 9,973 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 1.1%Here's Why - MarketBeat
Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) COO Sells 1,198 Shares of Stock - MarketBeat
Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel Sells 2,850 Shares of Stock - MarketBeat
CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know - MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 3.9%Here's Why - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.9% Following Insider Selling - Defense World
CRISPR Therapeutics: An Uninspiring Start For Casgevy - Seeking Alpha
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 3%Should You Sell? - MarketBeat
Why Is CRISPR Therapeutics (CRSP) Up 0.4% Since Last Earnings Report? - Yahoo Finance
Gene Editing Market Future Business Opportunities 2025-2032 | - openPR
Insider Buying: John Greene Acquires Shares of CRISPR Therapeutics AG - GuruFocus.com
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Crispr Therapeutics CEO sells shares worth $616,348 By Investing.com - Investing.com South Africa
Crispr Therapeutics general counsel sells shares worth $169,242 By Investing.com - Investing.com South Africa
Crispr Therapeutics general counsel sells shares worth $169,242 - Investing.com India
Crispr therapeutics COO Bruno Julianne sells $59,049 in common shares By Investing.com - Investing.com South Africa
Crispr therapeutics COO Bruno Julianne sells $59,049 in common shares - Investing.com India
Crispr Therapeutics CEO sells shares worth $616,348 - Investing.com
CRISPR Therapeutics AG Executives Sell Shares - TradingView
Oppenheimer & Co. Inc. Decreases Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 0.9%Still a Buy? - MarketBeat
ElevateBio taps Amazon’s genAI tools to design CRISPR therapeutics - Yahoo Finance
Jones Financial Companies Lllp Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Brokers Issue Forecasts for CRSP FY2027 Earnings - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading 0.9% HigherHere's What Happened - MarketBeat
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):